With the $2.8 billion acquisition deal of California’s Genomic Health officially completed, Madison-based Exact Sciences Corp. is calculating the estimated combined revenue earned by both companies for the recent fourth quarter is between $294 million and $296 million, according to preliminary, unaudited earnings from the Cologuard take-home colon cancer test maker.
Exact Sciences is expecting to report 477,000 completed Cologuard tests for the quarter, a 63% increase when compared with the year-ago quarter. For the 12-month period ending Dec. 31, 2019, the company is estimating revenue between $874.5 million and $876.5 million and full-year Cologuard test volume of 1.68 million, an increase of 80% relative to 2018.
In 2018, Exact Sciences reported full-year revenue of $454.5 million and 934,000 completed Cologuard tests.
Exact Sciences (Nasdaq: EXAS) closed the deal with Genomic Health on Nov. 8, 2019. Revenue from Genomic’s precision oncology business from the Nov. 8 closing date through Dec. 31, 2019, is expected to be between $65 million and $66 million.